News & Events about Biomarin Pharmaceutical Inc.
TipRanks Financial Blog
1 year ago
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN Research R... In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN –...
BioMarin Pharmaceutical (NASDAQ:BMRN Get Rating) had its price objective decreased by Guggenheim from $125.00 to $120.00 in a report published on Thursday morning, The Fly reports. Other equities research analysts have also recently issued reports about the stock. Oppenheimer cut shares of BioMarin ...
AIA Group Ltd lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) by 168.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,313 shares of the biotechnology companys stock after ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) CEO Jean Jacques Bienaime sold 10,000 shares of the companys stock in a transaction dated Thursday, April 6th. The stock was sold at an average price of $96.13, for a total transaction of $961,300.00. Following the completion of the transaction, ...
BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A PR Newswire SAN RAFAEL, Calif., March...